Massachusetts is currently home to 3202 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Boston, Worcester, Springfield and Burlington. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
NCT06190158
Recruiting
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Register for Updates
Respiratory Microbiota and Immune Response in CVID
NCT06173128
Recruiting
Common variable immunodeficiency (CVID) is the most prevalent symptomatic primary immunodeficiency. Respiratory ailments are the most frequent complications of CVID, with chronic pulmonary disease developing in 30-60% and even more experiencing frequent acute respiratory infections. This project aims to establish cutting-edge approaches to study pulmonary biology in CVID and apply novel bioinformatics strategies to study complex interactions among microbes and host cells by direct sampling of th... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: Boston Medical Center, Boston, Massachusetts
Conditions: CVID
Register for Updates
Shockwave Lithoplasty Compared to Cutting Balloon Treatment in Calcified Coronary Disease - A Randomized Controlled Trial
NCT06089135
Recruiting
The Short-Cut trial is a prospective, investigator-initiated, multicenter, randomized controlled trial that is designed to compare the efficacy of cutting balloon angioplasty vs. intravascular lithotripsy prior to drug-eluting stent implantation in patients with moderate to severely calcified coronary arteries.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
04/03/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Treatment in Calcified Coronary Disease
Register for Updates
Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
NCT05592015
Recruiting
This phase II trial tests whether ruxolitinib works to shrink tumors in patients with T-cell large granular lymphocyte leukemia. Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: T-Cell Large Granular Lymphocyte Leukemia
Register for Updates
Inter-lobar Fissure Completion in Patients With Failed Bronchoscopic Lung Volume Reduction
NCT05257681
Recruiting
The purpose of this protocol is to perform a pilot prospective controlled clinical trial to evaluate the potential role of lung fissure completion with pleural adhesiolysis strategy (experimental intervention) in severe emphysema/COPD patients with failed bronchoscopic lung volume reduction (BLVR) via the use of endobronchial valves (EBVs) therapy. In select patients, the lung fissure completion with adhesiolysis strategy will be performed by video-assisted thoracoscopic surgery (VATS) guided st... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
04/03/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Emphysema or COPD
Register for Updates
FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
NCT05135091
Recruiting
This clinical trial is designed to test whether a single image-guided intracerebral administration of inhibitory nerve cells, called interneurons (NRTX-1001), into subjects with drug-resistant unilateral mesial temporal lobe epilepsy (MTLE), with or without mesial temporal sclerosis (MTS), is safe (frequency of adverse events) and effective (seizure frequency). NRTX-1001 comprises human interneurons that secrete a neurotransmitter, gamma-aminobutyric acid (GABA).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/03/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Mesial Temporal Lobe Epilepsy
Register for Updates
Combined Zephyr Valve System With Inter-lobar Fissure Completion for Lung Volume Reduction in Emphysema
NCT04801108
Recruiting
The purpose of this protocol is to perform a pilot prospective randomized controlled clinical trial to evaluate the potential role of lung fissure completion strategy (experimental intervention) in addition to endobronchial valve (EBV) placement (representing "standard-of-care") in select patients with severe COPD/emphysema and with evidence for \<95% fissure completion between adjacent lung lobes. In select patients, lung fissure completion strategy will be performed by either video-assisted th... Read More
Gender:
ALL
Ages:
Between 40 years and 75 years
Trial Updated:
04/03/2025
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts
Conditions: Emphysema or COPD
Register for Updates
A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB)
NCT04752813
Recruiting
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Glioblastoma, Glioblastoma Multiforme
Register for Updates
Feasibility Tests for Various Prism Configurations for Visual Field Loss
NCT04424979
Recruiting
The investigators will develop and test different configurations of high-power prisms to expand the field of vision of patients with visual field loss to assist them with obstacle detection when walking. The study will involve multiple visits (typically four) to Schepens Eye Research Institute for fitting and testing with the prism glasses. The overall objective is to determine best designs and fitting parameters for implementation in prism devices for future clinical trials.
Gender:
ALL
Ages:
Between 7 years and 80 years
Trial Updated:
04/03/2025
Locations: Schepens Eye Research Institute, Boston, Massachusetts
Conditions: Hemianopia, Homonymous, Tunnel Vision, Visual Field Defect, Peripheral, Visual Field Constriction Bilateral, Visual Field Defect Homonymous Bilateral
Register for Updates
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
NCT03723928
Recruiting
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Lahey Hospital and Medical Center, Burlington, Massachusetts
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Positive, Prognostic Stage IV Breast Cancer AJCC v8, Elevated CA15-3 or CEA or CA27-29
Register for Updates
Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission
NCT02140255
Recruiting
The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.
Gender:
ALL
Ages:
48 hours and below
Trial Updated:
04/03/2025
Locations: Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts
Conditions: HIV Infection
Register for Updates
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
NCT06710548
Recruiting
The purpose of this study is to see whether a supportive intervention (REVITALIZE) reduces fatigue and its impact on daily life and activities for participants with ovarian cancer taking PARP inhibitors. The name of the study groups in this research study are: 1. REVITALIZE 2. Educational Materials
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Ovarian Cancer, Advanced Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Cancer, PARP Inhibitor, Fatigue Related to Cancer Treatment, Fatigue in Cancer Survivors
Register for Updates